Drug Profile
Ecallantide - Takeda
Alternative Names: CB-500,929; DX-88; EPI-KAL2; FOV 2302; KalbitorLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dyax
- Developer Cubist Pharmaceuticals; Dyax; Fovea Pharmaceuticals; Neopharm Ltd; Takeda
- Class Analgesics; Anti-inflammatories; Eye disorder therapies; Peptides; Recombinant proteins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
- Suspended Retinal oedema
- Discontinued Angioedema; Surgical blood loss
Most Recent Events
- 26 Dec 2022 Ecallantide is still in registration for Hereditary angioedema in Japan (Takeda website, December 2022)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 21 Dec 2018 Windtree Therapeutics merged with CVie Therapeutics to form Windtree Therapeutics